The medicinal use of cannabidiol (CBD) in Brazil has been an ongoing topic of significant debate and progress in recent years. While the benefits of CBD, particularly in the treatment of neurological conditions like epilepsy and chronic pain, have become widely recognized, the legal framework surrounding its use has been slow to catch up. In 2025, the country is still in the process of refining its regulations for CBD production and distribution, aiming to increase accessibility while ensuring the safety and efficacy of the treatments.

Regulatory Developments and Actions

The Brazilian government has been working on creating a clear regulatory path for the production, prescription, and commercialization of CBD-based products. In 2023, Brazil’s National Health Surveillance Agency (ANVISA) approved the use of CBD for medical purposes, but the restrictions were still tight. Since then, there have been notable steps taken to address these restrictions, most notably with the government outlining a regulatory action plan for cannabis in 2025, with a deadline for full implementation by September 2025.

This new framework includes the establishment of clear guidelines for:

• Cultivation: Brazil will set rules for local cultivation of cannabis for medical purposes, which will allow the country to begin producing its own CBD, reducing dependence on international imports.

• Production: Pharmaceutical companies will be able to produce CBD-based medicines locally, making them more affordable and accessible to patients.

• Prescription Guidelines: Medical professionals will receive clearer guidelines on the prescription of CBD, which includes ensuring that CBD can be prescribed in higher doses for patients with certain medical conditions.

Key Challenges

Despite these promising developments, several regulatory challenges remain, hindering the broader use of CBD in Brazil:

1. Legal and Bureaucratic Barriers:

   • Lack of clarity in the law: Many legal ambiguities still exist in the legislation, particularly regarding the process of importing and distributing cannabis products. There is also ongoing debate on whether patients should be allowed to cultivate cannabis for personal medicinal use, as is allowed in some other countries.

   • Regulatory enforcement: While ANVISA has moved forward with some regulatory measures, local health authorities, especially in more conservative states, may be slow to adopt new rules. This fragmentation of regulations could create disparities in patient access to CBD treatment.

2. Cost and Accessibility:

   • The cost of CBD treatments remains prohibitively high for many Brazilians. Though the government’s push for local production may reduce costs in the future, patients currently face steep prices, especially for imported medications.

   • Insurance companies are still reluctant to cover CBD-based treatments, citing regulatory uncertainties and cost concerns, leaving many patients to pay out of pocket.

3. Cultural and Social Stigma:

   • Cannabis remains a controversial subject in Brazil, largely due to its association with recreational marijuana use. Despite evidence of the positive medical applications of CBD, cultural and social stigma around cannabis consumption still poses an obstacle to widespread acceptance. Many patients are hesitant to discuss or seek CBD treatment due to fear of judgment or misunderstanding.

4. Medical Training and Awareness:

   • One of the biggest hurdles for expanding the use of CBD in Brazil is the lack of widespread knowledge among healthcare professionals. Although the medical community is increasingly open to the potential benefits of CBD, many doctors remain unfamiliar with its applications and how to prescribe it effectively.

   • Efforts are being made to educate doctors about CBD, but these programs need to be expanded and standardized across the country to ensure that patients receive informed, accurate treatment.

Looking Forward: A Path Toward Greater Access and Equity

The path toward greater access to CBD in Brazil remains challenging, but progress is being made. If the regulations scheduled for full implementation in September 2025 are followed through, Brazil could become a regional leader in the medical cannabis industry, offering a model for other Latin American countries.

There is also hope that more public health campaigns will help dispel myths surrounding cannabis use and promote a better understanding of its medicinal properties. With the right legal frameworks, education, and cultural shifts, CBD could become a routine part of treatment plans for patients suffering from various conditions, improving lives across Brazil.

As legal professionals and healthcare experts in Brazil continue to navigate these changes, the key will be ensuring that the regulatory environment remains adaptable, responsive to scientific evidence, and, above all, centered around patient well-being.